Simposio Subregional de Nuevas Vacunas: neumococo y rotavirus
San JoseCosta Rica
20-21 agosto 2007
Marc-Alain WiddowsonCenters for Disease Control and Prevention
La Carga Global del Rotavirus
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Epidemiology of rotavirus• Disease in young children
§ Virtually all children infected and ill by age five years§ Democratic virus§ Highest rates of disease between 6-24 mos.§ Uncommon before 3 months
• Single clinical syndrome – gastroenteritis§ Mild to very severe
• Natural infection confers protection against subsequent infection§ Higher protection against severe disease
• Worldwide distribution
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
All children will get at least one rotavirus infection early in life
Reproduced with permission from Velázquez et al. N Engl J Med. 1996;335:1022-1028.
1.00.90.80.70.60.50.40.30.20.1
3 6 9 12 15 18 21 24
Prob
abili
ty o
f rot
aviru
s in
fect
ion
Age (months)
1st infection
2nd infection
3rd infection
4th infection
5th infection
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Annual disease burden of rotavirus in the United States
3.5 - 4.0 millones1:1
500,0001:7
55-70,0001:72
20-40<1:100,000
Riesgo a 5 anos Eventos
Muertes
Hospitalizaciones
Casos de diarrea
Consultas
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
La carga global del RotavirusLa carga global del Rotavirus
527,000 (475,000 – 580,000)
2.3 millones
24 millones
114 millones
1 : 285
1 : 58
1 : 5
1 : 1
Riesgo a 5 anos Eventos
WHO estimates, 2004
Muertes
Hospitalizaciones
Casos de diarrea
Consultas
5% of all deaths in children < 5are due to rotavirus
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
1 dot = 1000 deaths
Estimated global distribution of the 527,000 annual deaths caused by rotavirus
Estimated global distribution of the 527,000 annual deaths caused by rotavirus
14,751(11-17,000)
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Estimated rate of rotavirus deaths per 100,000 population under five years of age.
Estimated rate of rotavirus deaths per 100,000 population under five years of age.
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 12 24 36 48
Age (months)
Cum
ulat
ive
% R
V po
sitiv
e
60
India
Myanmar
China
Vietnam
Thailand
Indonesia
Japan
TaiwanHong Kong
Malaysia
Korea
Age distribution of rotavirus hospitalizations in ARSN sites and United States
J Bresee EIDJ 2005
United States
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Differences in rotavirus epidemiology between developed and developing countries
DevelopedCountries9-15 mo.
65%Winter
4-5 commonUncommonUncommon
DevelopingCountries
6-9 mo.80%
Year-roundDiverse
CommonHIV, Malnutrition
Age - median- % <1year
SeasonalityRv StrainsCo-infectionsCo-morbidity
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Causes of severe acute gastroenteritis among children <5 years
OtherOther
Bacterial Bacterial
Rotavirus
Developed Countries Developing Countries
Unknown Unknown Rotavirus
A. Kapikian Fields Virology 2003
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
WHO’s Generic Protocol• Hospital-based surveillance• Simple data collection• Outcomes:
» Rates of rotavirus hospitalizations
» % Rv positive• Guidelines for strain typing• Platform for measuring
other outcomes» Outpatient visits» Costs» intussusception
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Global Rotavirus Surveillance
CDC, Atlanta
Murdoch Childrens Research InstituteMelbourne, Australia
MEDUNSAPretoria, S Africa
NMIMR, Univ. of GhanaLegon, Ghana
Health Protection AgencyLondon, UK
Reference Laboratory
PAHO (10)
SEARO/WPRO/EURO (14)
EMRO (10)
EURO (4)
AFRO (6)
Surveillance activities are scheduled to begin in 2006-2007
LEGEND
>40 countries
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Rotavirus hospitalizations in the Asian Rotavirus Surveillance Network, 2001-3
Median = 45%
Vietnam: 54%
Bresee, Nelson, Hummelman, Glass, JID, 2005
China: 46%
Korea: 73%
Malaysia: 49%Indonesia: 54%
Myanmar: 56%
Hong Kong: 30%
Taiwan: 44%
Thailand: 43%
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Proportion of hospitalizations attributable to rotavirus, Aug 2001 – July 2002, Asia
+16
+16
+21
-12 to +26+34+32
-5 to +4+1 to +29+5 to +33
DifferencePast studies, range % RV+ % RV+Site
38
29
54
45
Indonesia
MEDIAN
2849Malaysia
17, 17, 20, 25, 30, 33, 38, 55
43Thailand2256Myanmar2254Vietnam
26, 29, 34, 3530Hong Kong15, 27, 41, 4344Taiwan
26, 13, 4146China
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Updated rotavirus mortality estimate
2.4 – 2.91998Murray
2.51993WDR
1.562003CHERG
3.31992Bern
3.21990Martines
870,0003.51986IOM
4.61982Snyder
RV deathsYearStudyDD Deaths (millions)
YearStudy
39%608,000
25%
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Why is rotavirus mortality not dropping as fast?
• Sanitation, safe water and hygiene improvements will prevent bacterial & parasitic infections but less so rotavirus
• Antibiotics ineffective against rotavirus
• ORS may be less effective for rotavirus because of frequent vomiting
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
P[8]G47.5%
P[8]G152.2%
P[6] or P[8], G9
2%
other18.2%
P[8]G32.8%
P[4]G211.5%
Limited Number of Globally Common Strains
N=21,256 (1993-2003)Gentsch et al, JID, 2005
Rare or regionally common strains (25 strainstotal): P[4]G1 (1.3%), P[6]G2 (0.8%), P[6]G1 (0.6%), P[6]G8 (0.6%), P[4], G3 (0.5%)
5.5%
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Rotavirus strainsRotavirus strains
Gentsch et al, JID, 2005
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Number 1January 5, 2006Volume 354
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios, M.D., Irene Pérez-Schael, M.Sc., F. Raúl Velázquez, M.D., Hector Abate, M.D., Thomas Breuer, M.D., SueAnn Costa Clemens, M.D., Brigitte Cheuvart, Ph.D., Felix Espinoza, M.D., Paul Gillard, M.D., Bruce L. Innis, M.D., Yolanda Cervantes, M.D., Alexandre C. Linhares, M.D., Pío López, M.D., Mercedes Macías-Parra, M.D., Eduardo Ortega-Barría, M.D.,
Vesta Richardson, M.D., Doris Maribel Rivera-Medina, M.D., Luis Rivera, M.D., Belén Salinas, M.D., Noris Pavía-Ruz, M.D., Jorge Salmerón, M.D., Ricardo Rüttimann, M.D., Juan Carlos Tinoco, M.D.,
Pilar Rubio, M.D., Ernesto Nuñez, M.D., M. Lourdes Guerrero, M.D., Juan Pablo Yarzábal, M.D., Silvia Damaso, M.Sc., Nadia Tornieporth, M.D., Xavier Sáez-Llorens, M.D., Rodrigo F. Vergara,
M.D., Timo Vesikari, M.D., Alain Bouckenooghe, M.D., Ralf Clemens, M.D., Ph.D., Béatrice De Vos, M.D., Miguel O'Ryan, M.D., for the Human Rotavirus Vaccine Study Group
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Number 1January 5, 2006Volume 354
Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine
Timo Vesikari, M.D., David O. Matson, M.D., Ph.D., Penelope Dennehy, M.D., Pierre Van Damme, M.D., Ph.D., Mathuram Santosham, M.D., M.P.H., Zoe
Rodriguez, M.D., Michael J. Dallas, Ph.D., Joseph F. Heyse, Ph.D., Michelle G. Goveia, M.D., M.P.H., Steven B. Black, M.D., Henry R. Shinefield, M.D., Celia D.C.
Christie, M.D., M.P.H., Samuli Ylitalo, M.D., Robbin F. Itzler, Ph.D., Michele L. Coia, B.A., Matthew T. Onorato, B.S., Ben A. Adeyi, M.P.H., Gary S. Marshall,
M.D., Leif Gothefors, M.D., Dirk Campens, M.D., Aino Karvonen, M.D., James P. Watt, M.D., M.P.H., Katherine L. O'Brien, M.D., M.P.H., Mark J. DiNubile, M.D., H Fred Clark, D.V.M., Ph.D., John W. Boslego, M.D., Paul A. Offit, M.D., Penny M.
Heaton, M.D., for the Rotavirus Efficacy and Safety Trial (REST) Study Team PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
1. US FDA licenses RotaTeq2. ACIP recommends RotaTeq for routine
immunization of all American children3. EMEA licenses Rotarix4. Brazil, Panama, Venezuela, Mexico,
Nicaragua, El Salvador begin programs of routine childhood immunization
5. GAVI approved investment case for Phase 1
2006 – momentum builds
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Introduction of subsidized vaccine to GAVI-eligible countries
PATH: RVP
Europe, Latin America
Africa, Asia
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
GSK Rotarix® licensure (92 countries – 31 May, 2007):
Bahrain, Egypt, Jordan, Morocco, Oman, Pakistan, Qatar, SaudiArabia, UAE, Yemen
10Middle East
Bangladesh, Sri Lanka, Thailand3Southeast Asia
Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK
31Europe
Australia, Hong Kong, Malaysia, New Zealand, Philippines, Singapore, Taiwan
7Western Pacific
Benin, Burkina Faso, Cameroun, Central African Republic, Congo, DRCongo, Gabon, Guinea, Ivory Coast, Kenya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Nigeria, Senegal, South Africa, Togo
19Africa
Argentina, Aruba, Bolivia, Brazil, Chile, Colombia, Costa Rica, Curaçao, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Trinidad/Tobago, Venezuela
22Americas
Countries that have licensed Rotarix®WHO Region
Courtesy Dr Robin BiellikPDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Merck RotaTeq™ licensure (47 countries – March 1, 2007):
0SoutheastAsia
0Middle East
Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Turkey, UK
26Europe
Australia, Hong Kong, Taiwan3WesternPacific
DRCongo, Guinea, Kenya, Niger, Rwanda, Togo6Africa
Argentina, Canada, Curação, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Perú, Puerto Rico, USA
12AmericasCountries that have licensed RotaTeq®WHO Region
Courtesy Dr Robin Biellik
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
First rotavirus immunizations in Panama, Inaugurated by President Martin Torrijos and his wife, Vivien de Torrijos, March 14, 2006
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html
GRACIAS
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Strain diversity and trends
Kang et al JID, 2005
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
P[4]G2
P[8]G3
P[8]G4
otherP[6]G1
P[8]G1
P[8]G3
other
P[8]G4
P[6]G9P[6]G3
P[8]G1
P[4]G2P[8]G3
P[8]G4
mixed
P[9]G3
P[6]G2
P[8]G1
P[4]G2
P[8]G3P[8]G4
other
U.S., N=348 India, N=133
Examples of Unusual Strain Prevalence
Brazil, N=130 Malawi, N=100
P[6]G842%
P[4]G8 9%
P[8]G510%
P[8]G9P[6]G9
7.2% P[6]G917%
} P[6]G1, P[6]G2,P[6]G3, P[6]G4
J. Gentsch
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com
Detection rate of rotavirus in hospitalized diarrhea cases, 1986-1999 vs. 2000-2004
0
10
20
30
40
50
60
70
80
100 1000 10000 100000
GNP Per Capita
% R
V Po
sitiv
e
2000-2004 1986-1999
Low incomeLow-middle
incomeHigh-middle
income High income
Parashar EIDJ, 2006
PDF created with FinePrint pdfFactory trial version http://www.pdffactory.com